BF-derm1Alternative Names: BF-derm 1
Latest Information Update: 20 Aug 2015
At a glance
- Originator Biofrontera AG
- Class Skin disorder therapies
- Mechanism of Action Histidine decarboxylase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
- Available For Licensing Yes - Urticaria
Highest Development Phases
- Phase II Urticaria